Can potassium citrate replace sodium bicarbonate and potassium chloride of oral rehydration solution?

M R ISLAM

International Centre for Diarrhoeal Disease Research, Bangladesh

SUMMARY Ninety four children aged less than 5 years with diarrhoeal dehydration and acidosis were treated randomly with either World Health Organisation (WHO) oral rehydration solution containing sodium chloride, potassium chloride, sodium bicarbonate and glucose or an oral solution with tripotassium citrate monohydrate replacing the sodium bicarbonate and potassium chloride in the WHO solution. Fifty five children (58%) were hypokalaemic (potassium less than 3.5 mmol/l) on admission. All but two in the citrate group were successfully treated. There were no significant differences in rehydration solution intake, stool output, gain in body weight, and fall in plasma specific gravity and haematocrit between the two treatment groups after 48 hours’ treatment. Significant improvement in the serum potassium concentration was observed in the hypokalaemic children receiving potassium citrate solution compared with children receiving WHO solution after 24 and 48 hours’ treatment. None developed hyperkalaemia. Although children receiving potassium citrate solution corrected their acidosis at a slower rate than the WHO solution group during the first 24 hours, by 48 hours satisfactory correction was observed in all. Tripotassium citrate can safely replace sodium bicarbonate and potassium chloride and may be the most useful and beneficial treatment for diarrhoea and associated hypokalaemia.

Although the principles of appropriate formulation of oral rehydration solution have been extensively studied, controversies still remain regarding the electrolyte composition. The current World Health Organisation (WHO) oral rehydration solution, which contains bicarbonate, has some practical disadvantages when packed and stored under climatic conditions of high humidity and temperature. In these circumstances bicarbonate reacts with glucose or sucrose resulting in a brownish discolouration which is less acceptable to patients. The potassium concentration (20 mmol/l) in WHO solution is not adequate for the treatment of undernourished children with depleted total body potassium who may lose more than 30 mmol potassium/l of stool while suffering diarrhoea due to cholera, Escherichia coli, or rotavirus infection. Our previous study has shown that sodium citrate is as effective as sodium bicarbonate in correcting acidosis in diarrhoea.

Tripotassium citrate monohydrate is a stable crystalline salt that will not cause discolouration so readily when mixed with glucose or sucrose and stored in packets under conditions of high humidity. Thus an oral rehydration solution containing 10 mmol/l (3.24 g) of tripotassium citrate/l will provide both adequate alkali and a higher concentration of potassium than the WHO solution.

We have studied whether (a) potassium citrate in oral rehydration solution can replace sodium bicarbonate and potassium chloride adequately, (b) the increased concentration of potassium (30 mmol/l) corrects hypokalaemia better than WHO solution, and (c) the increased concentration of potassium causes hyperkalaemia in normokalaemic patients.

Patients and methods

This double blind, randomised study was carried out at the International Centre for Diarrhoeal Disease Research, Bangladesh from April to September 1982 on children below 5 years of age. These children were admitted with mild or moderate degrees of dehydration. Informed consent was obtained from parents or legal guardians of the children after the nature of the procedures had been fully explained. The biochemistry laboratory personnel prepared the packets of oral rehydration solutions, confirmed their chemical concentrations, and coded them. Nursing staff dissolved the packets according to a random schedule before giving the solution to the patients.
Children in the potassium citrate group received a solution containing sodium 90, potassium 30, chloride 90, trisaccharide 10, and glucose 111 mmol/l (sodium chloride 3-5 g, potassium citrate 3-24 g, and glucose 20 g/l). Children in the WHO solution group received solution containing sodium 90, potassium 20, chloride 80, bicarbonate 30, and glucose 111 mmol/l (sodium chloride 3-5 g, potassium chloride 1-5 g, sodium bicarbonate 2-5 g, and glucose 20 g/l).

Patients were treated exclusively with an oral rehydration solution. Total volume given during the first six hours was 50 ml/kg body weight for mild and 100 ml/kg for moderate dehydration. Oral treatment was continued to match losses by stool and vomit losses until the diarrhoea stopped. Intake of solution and stool output were recorded at 8 hour intervals.

Patients who failed to be rehydrated or to maintain hydration on oral solution alone were considered as treatment failures and were excluded from the study. These patients were rehydrated with intravenous fluid. The criteria for failure of treatment were based on clinical assessment supported by intake and output balance and failure to gain body weight. Breast milk, when available, or diluted cows' milk (half strength) were allowed four hours after hospital admission.

Blood samples were drawn for estimation of haematocrit, plasma specific gravity (by Goldberg refractometer) and, electrolytes (by IL flame photometer) on admission and at 24 and 48 hours after the start of oral treatment. Adequate samples of stool and urine were sent simultaneously for estimation of the potassium concentration and serum electrolyte values. Stool samples were cultured on admission for Vibro cholerae, Salmonella sp, Shigella sp, and enterotoxigenic Escherichia coli. E coli isolates were tested for both heat labile and heat stable enterotoxins. Rotavirus was tested by ELISA method.

The nutritional state of the children was assessed by weight for age index—the discharge weight was determined as a percentage of the National Center for Health Statistics median for age and sex. Hypokalaemic children whose serum potassium concentration on admission was less than 3-5 mmol/l were considered as a separate group than the normokalaemic children for data analysis. Statistical tests were performed using the Student's t test and χ² test. Data from two children who failed treatment with citrate solution were excluded from analysis.

### Results

Ninety four children aged under 5 years were studied. Fifty five of them were hypokalaemic (potassium less than 3-5 mmol/l) and 39 were normokalaemic (potassium 3-5 to 5-5 mmol/l), none were hyperkalaemic. Twenty seven hypokalaemic children received potassium citrate rehydration solution and 28 received WHO solution. Nineteen normokalaemic children received the potassium citrate and 20 the WHO solution. Most (53%) of these children were between 7 and 12 months of age and showed signs of moderate malnutrition.

Clinical characteristics of the children at the time of hospital admission in relation to age, sex, duration of diarrhoea, body weight, nutritional status, and haematocrit were not different between the groups. About 50% of the children were admitted with signs of moderate dehydration and acidosis as determined by serum bicarbonate (less than 15 mmol/l). All 48 (100%) children receiving the WHO solution and 44 of 46 (96%) children receiving potassium citrate solution were successfully rehydrated and maintained their hydration status well until diarrhoea stopped. The two in whom oral treatment failed (cholera patients) were withdrawn from the study. Although they drank sufficient rehydration solution they remained dehydrated and failed to gain body weight due to persistent vomiting and heavy purging (greater than 10 ml/kg per hour). They were subsequently treated with intravenous fluid. Frequency of vomiting in patients receiving

### Table 1  Comparison of the intake of oral rehydration solutions (ORS) and stool output after 24 hours and 48 hours treatment with potassium citrate ORS and WHO ORS (values, mean (SD))

<table>
<thead>
<tr>
<th></th>
<th>Hypokalaemic group (K&lt;3-5 mmol/l)</th>
<th>Normokalaemic group (K 3-5-5-5 mmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K citrate ORS</td>
<td>WHO ORS</td>
</tr>
<tr>
<td></td>
<td>(n=27)</td>
<td>(n=28)</td>
</tr>
<tr>
<td>ORS intake (ml/kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>First 24 hours</td>
<td>251-3 (130-9)</td>
<td>300-4 (242-8)</td>
</tr>
<tr>
<td>Second 24 hours</td>
<td>195-1 (102-6)</td>
<td>247-6 (275-1)</td>
</tr>
<tr>
<td>Stool output (ml/kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>First 24 hours</td>
<td>146-2 (124-4)</td>
<td>182-0 (192-5)</td>
</tr>
<tr>
<td>Second 24 hours</td>
<td>157-7 (103-6)</td>
<td>173-6 (203-5)</td>
</tr>
</tbody>
</table>
potassium citrate solution was not significantly greater than in those receiving WHO solution. No significant inter-group difference in the intake of solution and output of stool was observed (Table 1).

A significant improvement in the serum potassium concentration was observed both at 24 hours (P<0.02) and at 48 hours (P<0.01) after the start of treatment in the group receiving potassium citrate rehydration solution.

Only three patients in the potassium citrate group compared with 11 in WHO group remained hypokalaemic 48 hours after the beginning of treatment. No patient developed hyperkalaemia during treatment. In both hypokalaemic and normokalaemic children receiving potassium citrate solution acidosis resolved more slowly than in those receiving WHO solution during the first 24 hours of treatment. By 48 hours, however, satisfactory correction of acidosis was observed in all children (Table 2). Serum sodium and chloride, stool potassium contents at 0, 24, and 48 hours showed no significant differences between groups. All patients passed urine satisfactorily within 12 hours. Hypokalaemic children conserved potassium significantly better than normokalaemic children (Table 2).

The aetiological agents identified in the patients were *V cholerae* (2), *Shigella* sp (1), ETEC (8), and rotavirus (12) in the potassium citrate group, and *V cholerae* (3), *Shigella* sp (1), ETEC (8), and rotavirus (12) in the WHO group.

Discussion

This study shows that potassium citrate salt can be used in place of sodium bicarbonate and potassium chloride in oral rehydration solution, thereby reducing the number of ingredients from four to three. This study further confirms the findings of Nalin and co-workers, that hypokalaemia can be treated satisfactorily by using a higher concentration of potassium without any danger of hyperkalaemia. Relatively fewer patients remained hypokalaemic after treatment with a higher concentration of potassium. This suggests that a higher concentration of potassium is necessary to treat hypokalaemia and associated diarrhoea, particularly in developing countries where malnutrition with associated total body potassium depletion is a major health problem. Hypokalaemic children excrete less potassium in urine as most of the potassium is conserved by the body to resolve the hypokalaemia.

The reason for delayed correction of biochemical acidosis in patients receiving potassium citrate solution is not fully understood and needs further investigations. Delayed resolution of acidosis may, however, have little practical importance.
Can potassium citrate replace sodium bicarbonate and potassium chloride of oral rehydration solution? 855

The cost effectiveness of the two types of solutions has been assessed: in Bangladesh 100 packets of potassium citrate solution will cost US $9.8 and WHO solution US $8.00. This small increase in cost is negligible when we compare relative advantages of the two types of solution. Moreover, citrate based salt can be easily made in tablet form for convenient dispensing.

These advantages over the WHO oral rehydration solution have important implications in developing countries where diarrhoea, malnutrition, and hypokalaemia are interlinked and where there is great need for oral rehydration therapy.

This research was supported by the International Centre for Diarrhoeal Disease Research, Bangladesh. I thank Dr Thomas Butler for his suggestions and revisions of the paper, Mr Meer Md Ramzan Ali for secretarial work and the staff of the Clinical Research Unit for help and cooperation.

References
1 Hirschhorn N. Single solution for oral therapy of diarrhoea. Lancet 1975;i:1049.

Correspondence to Dr M R Islam, ICDDR, GPO Box 128, Dhaka–2, Bangladesh.

Received 9 April 1985